Closed joseph-rickert closed 3 weeks ago
The idea of a Golden suite of packages being available for all sponsors and regulatory agencies sounds like a dream. We all agree that these packages are "gold" and don't need to be assessed internally or externally for validation purpose and so we can focus on others.
Question related to this statement: "One suggestion that has gained some traction is that sponsors use the previous minor and latest patched R version for a submission." - How close to a DB lock would one switch the R version used for the CSR analysis? Even in a change cycle of 2 times per year, considering that you do not want to risk timelines due to a last minute change of R version, by the time you reach "submission" you may have quite an "old" R version. Is anyone aware of any potential issues/problems (from Regulatory perspective) with this until now? Or do I misinterpret something here? Note: I have zero personal experience with R based submissions.
Question related to this statement: "One suggestion that has gained some traction is that sponsors use the previous minor and latest patched R version for a submission." - How close to a DB lock would one switch the R version used for the CSR analysis? Even in a change cycle of 2 times per year, considering that you do not want to risk timelines due to a last minute change of R version, by the time you reach "submission" you may have quite an "old" R version. Is anyone aware of any potential issues/problems (from Regulatory perspective) with this until now? Or do I misinterpret something here? Note: I have zero personal experience with R based submissions.
I would not switch R versions between a lock and CSR unless there is some huge risk to the sponsor and regulatory agency. Hopefully, very unlikely to ever happen!
I think engaging with the reviewers early is very important especially if the study is going to happen over many years. The regulatory agencies can usually get access to R versions and prepare accordingly.
This blog post resonates a lot with me. Back in the Old World, I know that there is some work being done on CE approval of medical software. Here too, reproducibility of results is a big expectation similar to the FDA approval processes.
I don't think R versioning is as important as it was a few years ago. Namely, renv has matured a good deal. So I would say I am leaning towards the Roche
and Eli Lilly
way of doing things. renv can also address package versions, on top of the R release version itself and imo should be the standard practice for 'snapshotting'.
Please add comments on the R Consortium Blog Post under this issue.